US OptionsDetailed Quotes
GPCR250117P27500
- 1.00
- -0.30-23.08%
15min DelayTrading Jan 6 12:44 ET
1.00High1.00Low
1.00Open1.30Pre Close20 Volume1.73K Open Interest27.50Strike Price2.00KTurnover72.43%IV5.41%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier11DDays to Expiry1.00Extrinsic Value100Contract SizeAmericanOptions Type-0.4092Delta0.1098Gamma26.06Leverage Ratio-0.0620Theta-0.0035Rho-10.66Eff Leverage0.0190Vega
Structure Therapeutics Stock Discussion
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co (LLY.US)$ $Novo-Nordisk A/S (NVO.US)$ $Structure Therapeutics (GPCR.US)$ $Viking Therapeutics (VKTX.US)$ $Lipocine (LPCN.US)$
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co (LLY.US)$ Orforglipron and $Structure Therapeutics (GPCR.US)$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
On fire
Therapeutics Inc, a leading biopharmaceutical company, public offer at $31.90 per share USD for the acquisition of 17 million shares. The offer is subject to closing on June 7, 2024. This move reflects the company's commitment to expanding its market presence and fostering financial growth. Investors and stakeholders are urged to capitalize on this lucrative opportunity. Therapeutics Inc antici...
No comment yet